semaglutide cardiovascular outcomes news today 2025 Oral and in Patients with Type 2 Diabetes Cardiovascular Outcomes Associated with Semaglutide

Description

Altimmune (NASDAQ:ALT) management used an appearance at the Goldman Sachs Global Healthcare Conference to outline the companys focus on pemvidutide, its lead metabolic and liver disease drug candidate, and to discuss the planned Phase 3 program in metabolic dysfunction-associated steatohepatitis, o

Schedule your session and meet your new, empowered self.

Explore how GLP-1 medications are transforming weight loss by regulating appetite and supporting sustainable results

Here's what experts think.

Sun Pharma Gets Approval for Generic Semaglutide Sun Pharmaceutical has received regulatory clearance to develop and market a generic version of semaglutide, intensifying competition in the rapidly growing obesity and diabetes treatment market